A national drug trial being organized at Upstate aims to find a safer treatment for the chronic inflammatory disease lupus.
On this week’s “HealthLink on Air,” Dr. Andras Perl, the chief of rheumatology, describes how the potential new treatment is designed to suppress the immune system using an oral form of a modified natural amino acid called acetylcysteine.
Upstate will lead the study, which will involve 20 academic medical centers across the United States. For more information about the drug trial, call 315-464-1779.
Also on the show, Dr. Andrea Shaw tells how the pandemic has affected the refugee population in Syracuse, and Dr. David Lehmann tells how the homeless population has been impacted. Listen this Sunday, October 11 at 6 a.m. and 9 p.m. for more.
